HCW Biologics (NASDAQ:HCWB) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of HCW Biologics (NASDAQ:HCWB) from a hold rating to a sell rating in a report issued on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of HCW Biologics in a report on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $30.00.

HCW Biologics Stock Down 7.5%

Shares of HCWB stock opened at $1.48 on Friday. HCW Biologics has a 12-month low of $1.47 and a 12-month high of $27.30. The company has a market capitalization of $3.32 million, a PE ratio of -0.05 and a beta of 2.41. The firm has a 50 day moving average price of $2.41 and a two-hundred day moving average price of $4.18.

HCW Biologics (NASDAQ:HCWB) last posted its earnings results on Friday, August 14th. The company reported ($11.58) EPS for the quarter, missing the consensus estimate of ($1.98) by ($9.60). The firm had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.14 million. HCW Biologics had a negative net margin of 83.03% and a negative return on equity of 262.33%.

About HCW Biologics

HCW Biologics Inc (NASDAQ: HCWB) is a clinical-stage biotechnology company developing immunotherapies for diseases associated with chronic inflammation, including inflammation linked to aging and age-related conditions. The company’s research is focused on modulating the immune system to address “inflammaging,” a persistent, low-grade inflammatory state that may contribute to multiple diseases.

HCW Biologics’ product candidates are based on its proprietary immunotherapy platform, which is designed to combine immune-stimulating and inflammation-modulating activities in a single biologic.